Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122925 · ClinicalTrials.gov registry record
TCA Cycle in the Dentate in Friedreich's Ataxia
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 20
- Enrollment target
NCT03122925: Completed study, sponsored by University of Minnesota.
NCT03122925 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03122925 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
OBJECTIVE: To measure the tricarboxylic acid (TCA) cycle rate in the dentate nucleus in a group of control subjects and subjects with Friedreich's Ataxia (FRDA). HYPOTHESIS: The TCA cycle rate will be lower in FRDA subjects than in controls APPROACH: The investigators will infuse carbon-13 (13C) labeled glucose and measure the rate of 13C label incorporation from glucose to glutamate in the brain using in vivo magnetic resonance spectroscopy.
Primary Outcome
value between 0 to 2 micromol/g/min
Interventions
- DEVICE MR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-08-29 |
| Est. Completion | 2023-01-11 |
What the finished NCT03122925 record still lists
NCT03122925 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which MR is the first listed.
NCT03122925 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03122925 about?
NCT03122925 is a clinical study titled "TCA Cycle in the Dentate in Friedreich's Ataxia". OBJECTIVE: To measure the tricarboxylic acid (TCA) cycle rate in the dentate nucleus in a group of control subjects and subjects with Friedreich's Ataxia (FRDA). HYPOTHESIS: The TCA cycle rate will be lower in FRDA subjects than in controls APPROACH: The investigators will infuse carbon-13 (13C) la...
What is the current status of trial NCT03122925?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2017-08-29. Estimated completion is 2023-01-11.
What interventions are being tested in trial NCT03122925?
The interventions under investigation include: MR (DEVICE).
Who is sponsoring clinical trial NCT03122925?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI